Investing

Halozyme Therapeutics : HALO

HALO

Stock Data

$63.96

$0.30 (0.47%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Halozyme Therapeutics Inc is a biopharmaceutical company that specializes in developing and commercializing innovative enzyme-based therapies. Utilizing its patented recombinant human hyaluronidase enzyme (rHuPH20), Halozyme enhances the delivery of injectable biologics, including monoclonal antibodies and other therapeutic molecules. Its product lineup addresses a variety of medical conditions, from hydration and drug dispersion to treating chronic diseases such as HIV, multiple sclerosis, and various cancers. Founded in 1998, Halozyme is headquartered in San Diego, California, serving a global market.

All Halozyme Therapeutics Articles

52 Articles

Ian Cooper | Aug 6, 2025 at 8:04 AM EDT

Analysts Just Upgraded these Five Stocks

Here are a few recent upgrades you may want to pay attention to. Palantir Technologies Palantir Technologies (NYSE: PLTR |…

Joshua Rodriguez | Jul 17, 2024 at 9:22 AM EDT

Add These 5 Hot Biotech Stocks In July

Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in…

Lee Jackson | May 11, 2023 at 8:52 AM EDT

Thursday’s Top Analyst Upgrades and Downgrades: Airbnb, Antero Midstream, Exact Sciences, GitLab, Lumentum, Nektar Therapeutics, PayPal and More

Thursday's top analyst upgrades and downgrades included Airbnb, Alcon, Antero Midstream, Exact Sciences, GitLab, GlobalFoundries, Halozyme Therapeutics, Lumentum, Nektar Therapeutics,…

Chris Lange | Jun 14, 2021 at 9:17 AM EDT

Monday’s Analyst Upgrades and Downgrades: Chipotle, CRISPR, Hess Midstream, iMedia, Kinder Morgan, Wendy’s and More

Monday’s top analyst upgrades and downgrades included Chipotle Mexican Grill, CRISPR, Hess Midstream, iMedia Brands, Kinder Morgan, Wendy’s and more.

Lee Jackson | May 17, 2021 at 8:50 AM EDT

Monday’s Top Analyst Upgrades and Downgrades: Foot Locker, Halozyme Therapeutics, Kimberly-Clark, Occidental Petroleum, Texas Roadhouse, Trip.com and more

Monday's top analyst upgrades and downgrades included Foot Locker, Halozyme Therapeutics, Kimberley-Clark, Occidental Petroleum, Texas Roadhouse, Trip.com and Williams Companies.

Lee Jackson | Jan 21, 2021 at 8:56 AM EST

Top Analyst Upgrades and Downgrades: Alphabet, Chevron, Citigroup, Facebook, Fastly, Paypal, Snap, Twitter, Under Armour and More

Thursday's top analyst upgrades and downgrades included Alphabet, Chevron, Citigroup, Facebook, Fastly, Paypal, Snap, Twitter and Under Armour.

Jon C. Ogg | Aug 23, 2018 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: Aetna, Analog Devices, Lowe’s, Merck, Pfizer, Plug Power, Qualcomm, Target and More

The top analyst upgrades, downgrades and initiations seen on Thursday include Aetna, Analog Devices, Lowe's, Merck, Pfizer, Plug Power, Qualcomm…

Jon C. Ogg | Dec 18, 2017 at 11:50 AM EST

50 Mid-Cap and Larger Stocks More Than Doubled in 2017

With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50…

Chris Lange | Sep 14, 2017 at 8:45 AM EDT

Halozyme Therapeutics Wins Big on Roche License Agreement

Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its…

Chris Lange | Jan 5, 2017 at 11:40 AM EST

Why These 5 Biopharma Stocks Are Making Massive Gains on Thursday

As the markets are continuing to heat up, a few biopharma stocks made massive gains on Thursday. There is a…

Chris Lange | Mar 6, 2016 at 10:40 AM EST

3 Top Biopharma Movers of the Past Week

Over the past week, Halozyme Therapeutics and a couple of other biotech companies made impressive runs.

Chris Lange | Jan 16, 2016 at 10:20 AM EST

4 Top BioPharma Movers of the Past Week

These biotech companies stood out from the rest with big moves over the course of the past week.

Chris Lange | Jan 11, 2016 at 1:15 PM EST

Halozyme Therapeutics Sinks on Business Update

Halozyme Therapeutics hit a new 52-week low in Monday's session following the release of a business update at JPMorgan’s 34th…

Chris Lange | Jun 3, 2015 at 10:30 AM EDT

How Halozyme Will Continue to Grow With Its New Deal

Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.

Jon C. Ogg | Dec 27, 2014 at 9:20 AM EST

13 Analyst Stocks at $10 and Under With Huge Implied Upside

Many investors are looking for where to put their money now that the Dow Jones Industrial Average has hit 18,000.